CytomX Therapeutics, Inc. (CTMX) — Estimates & Forecasts
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
Popular:
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
| Metric | 2022 | 2023 | 2024 | 2025E | 2026E | 2027E | 2028E |
|---|---|---|---|---|---|---|---|
| Net Income | $-99M | $-569,000 | $32M | $30M | $61M | $121M | $165M |
| EPS (Diluted) | $-1.48 | $-0.01 | $0.38 | $0.33 | $0.60 | $1.08 | $1.33 |
| YoY Growth | — | — | — | -4.9% | +102.4% | +98.1% | +35.4% |
| Net Margin | -186.8% | -0.6% | 23.1% | 23.7% | 33.5% | 44.6% | 49.9% |
| Metric | 2024A | 2025E | 2026E | 2027E | 2028E |
|---|---|---|---|---|---|
| Revenue | $138M | $128M | $183M | $273M | $329M |
| Net Income | $32M | $30M | $61M | $121M | $165M |
| EPS (Diluted) | $0.38 | $0.33 | $0.60 | $1.08 | $1.33 |
| Free Cash Flow | $-87M | $64M | $92M | $136M | $165M |
Treat point estimates cautiously; use wider scenario ranges and position sizing discipline.
CytomX Therapeutics, Inc.'s projected EPS for the next fiscal year is $0.33. This estimate blends our quantitative model with Wall Street analyst consensus and carries a confidence score of 31/100. The model factors in revenue trajectory, margin path, and share buyback trends to arrive at this figure.
Our scenario-based model produces three price targets for CytomX Therapeutics, Inc.: Bear case $-37, Base case $8, and Bull case $5. These targets are derived by applying the median historical P/E ratio to forward EPS estimates under each growth scenario. They are not buy/sell recommendations.
CytomX Therapeutics, Inc.'s projected revenue growth for the next fiscal year is 12.3%, reaching approximately $0.1B in total revenue. Growth estimates are probability-weighted and blend analyst consensus with our CAGR extrapolation model. Outer years (FY+3, FY+4) fade toward industry median growth rates.
Accuracy depends on several measurable factors. Our model confidence score of 31/100 is computed from revenue predictability (25% weight), margin stability (20%), historical earnings beat rate (20%), data depth (15%), analyst coverage (10%), and model-consensus agreement (10%). Currently expanding margins support higher forecast reliability. No forecast model is perfect — always cross-reference with your own analysis.
CytomX Therapeutics, Inc.'s forward operating margin is estimated at 28.5% for the next fiscal year. The margin trend is currently "expanding". Our model tracks margin mean-reversion patterns and adjusts for sector-specific cost dynamics. Operating leverage is a key driver of EPS growth beyond top-line revenue expansion.
The v2 model uses a multi-step process: (1) Revenue is projected via blended CAGR with probability weighting, (2) Operating and net margins follow a mean-reversion path calibrated to sector norms, (3) EPS is derived from net income divided by projected diluted shares (accounting for buyback trends), (4) For FY+1 and FY+2, estimates are blended with analyst consensus based on coverage depth, (5) Price targets apply median historical P/E to forward EPS under bear/base/bull growth scenarios. All inputs are from public filings and third-party data providers.
The bear case ($-37) assumes P25 revenue growth, worst-case margins, and multiple compression. Key risks include: unexpected margin contraction, revenue deceleration below model floor, regulatory headwinds, macro deterioration, or competitive disruption. A confidence score below 60 suggests higher estimate volatility. Always size positions according to the full scenario range, not just the base case.
Our model is above Wall Street consensus with a 185.1% gap. For FY+1, analyst estimates blend with our model at 23% analyst weight. By FY+3 and FY+4, estimates are purely model-driven as analyst coverage thins out at longer horizons.